Evaluating combination therapies for asthma: pros, cons and comparative benefits

Research output: Contribution to journalReview articlepeer-review

Abstract

Combination therapies with inhaled corticosteroids (ICS) and either long-acting ß2 agonists (LABA) or leukotriene receptor antagonists (LTRA) are commonly used to help patients maintain control of their asthma. LABA and LTRA have different mechanisms of action and both provide complementary benefits when combined with ICS. This paper compares the two regimens based on recent clinical trial data, evaluates their efficacy on various clinical and quality of life outcomes, and discusses the importance of therapy choice in people with specific asthma phenotypes. The potential of new dosing strategies, including adjustable maintenance therapy and single-inhaler maintenance and reliever therapy is also reviewed. Given the variety of outcomes, phenotypes, and treatment strategies that must be considered, the importance of individualized management is emphasized.
Original languageEnglish
Pages (from-to)149-161
JournalTherapeutic Advances in Respiratory Disease
Volume2
Issue number3
DOIs
Publication statusPublished - 2008

Subject classification (UKÄ)

  • Respiratory Medicine and Allergy

Fingerprint

Dive into the research topics of 'Evaluating combination therapies for asthma: pros, cons and comparative benefits'. Together they form a unique fingerprint.

Cite this